🇺🇸 Onabotulinumtoxin A in United States

14 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 14

Most-reported reactions

1. Feeling Abnormal — 2 reports (14.29%)
2. Myalgia — 2 reports (14.29%)
3. Neck Pain — 2 reports (14.29%)
4. Pain — 2 reports (14.29%)
5. Abdominal Pain Upper — 1 report (7.14%)
6. Asthenia — 1 report (7.14%)
7. Blood Pressure Increased — 1 report (7.14%)
8. Chills — 1 report (7.14%)
9. Cholecystitis — 1 report (7.14%)
10. Dizziness — 1 report (7.14%)

Source database →

Frequently asked questions

Is Onabotulinumtoxin A approved in United States?

Onabotulinumtoxin A does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Onabotulinumtoxin A in United States?

Wake Forest University Health Sciences is the originator. The local marketing authorisation holder may differ — check the official source linked above.